Brief: Synlogic Says Realignment Is Estimated To Reduce Company's Workforce By About 25%
Brief: Synlogic Announces Synb1353 Achieves Proof Of Mechanism For Treatment Of Homocystinuria And Provides Business Update
Brief: Synlogic Inc - On November 22, 2022, Unit Entered Into A Statement Of Work (The “Sow”) With Azzur Cleanrooms-On-Demand – Boston, Llc
Synlogic Inc reports results for the quarter ended in September - Earnings Summary
Brief: Synlogic Reports Q3 Loss Of $0.25 Per Share
Brief: Synlogic Inc Reports Q3 Loss Of $0.25 Per Share
Synlogic Inc expected to post a loss of 23 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-P&G, Acutus Medical, Amazon
U.S. STOCKS ON THE MOVE-Sonendo, Albertsons, Netflix
U.S. STOCKS ON THE MOVE-Baker Hughes, Akouos, Kalera
Synlogic jumps on positive trial data for blood disorder treatment
Brief: Synlogic Achieves Research Milestone In Collaboration With Roche For Development Of Novel Synthetic Biotic To Treat Inflammatory Bowel Disease
Brief: Synlogic Granted FDA Fast Track Designation For SYNB1353 For The Treatment Of Homocystinuria
Synlogic Inc reports results for the quarter ended in June - Earnings Summary
Brief: Synlogic announces synthetic biotic for gout developed in partnership with Ginkgo Bioworks
Brief: Synlogic Inc - $106.8 million in cash, cash equivalents and short-term investments support projected runway into 2024
Brief: Synlogic reports Q2 results
Synlogic Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Synlogic Initiates Phase 1 Study Of Synb1353 For Treatment Of Homocystinuria